| 0.0941 -0.076 (-44.65%) | 05-07 12:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.19 | 1-year : | 0.22 |
| Resists | First : | 0.16 | Second : | 0.19 |
| Pivot price | 0.12  |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.15 |
MA(20) : | 0.12 |
| MA(100) : | 0.45 |
MA(250) : | 0.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 80.7 | D(3) : | 80 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 1.98 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PTN ] has closed below upper band by 25.7%. Bollinger Bands are 61.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.16 - 0.16 | 0.16 - 0.16 |
| Low: | 0.15 - 0.15 | 0.15 - 0.15 |
| Close: | 0.15 - 0.15 | 0.15 - 0.15 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Tue, 11 Nov 2025
Why analysts raise outlook for Palatin Technologies Inc. (PTN) stock - 2025 Market Outlook & Community Verified Trade Alerts - newser.com
Mon, 10 Nov 2025
Can Palatin Technologies Inc. (PTN) stock stage a strong rebound this quarter - Trade Volume Report & Short-Term High Return Ideas - newser.com
Mon, 10 Nov 2025
Why analysts raise outlook for Palatin Technologies Inc. (PTN) stock - July 2025 Action & Momentum Based Trading Ideas - newser.com
Thu, 06 Nov 2025
Palatin (OTCQB: PTNT) reports MC4R + tirzepatide showed greater weight loss - Stock Titan
Thu, 06 Nov 2025
Why analysts raise outlook for Palatin Technologies Inc. (PTN) stock - July 2025 EndofMonth & Community Consensus Stock Picks - newser.com
Thu, 08 May 2025
Palatin Technologies Announces Closing of Reduced Public Offering - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 1,370 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | -2.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -555.3 % |
| Return on Assets (ttm) | -110.7 % |
| Return on Equity (ttm) | -623.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 0.49 |
| Price to Cash Flow | -0.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|